PriceTargets.com logo

NASDAQ:BLFS - BioLife Solutions Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $46.67
  • Forecasted Upside: 33.72 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$34.90 As of 04/14/2021 11:05 AM ET
▲ +0.25 (0.72%)
1 month | 3 months | 12 months
Get New BioLife Solutions Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLFS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$46.67
▲ +33.72% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for BioLife Solutions in the last 3 months. The average price target is $46.67, with a high forecast of $61.00 and a low forecast of $17.00. The average price target represents a 33.72% upside from the last price of $34.90.
Buy
The current consensus among 10 contributing investment analysts is to buy stock in BioLife Solutions. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/17/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/15/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/13/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2021KeyCorpBoost Price TargetOverweight$40.00 ➝ $50.00Low
i
3/29/2021BenchmarkUpgradeHold ➝ Buy$54.00N/A
i
3/24/2021B. RileyBoost Price Target$35.50 ➝ $61.00Low
i
Rating by M. Wiesenberger at B. Riley
3/23/2021Maxim GroupBoost Price TargetBuy$40.00 ➝ $60.00High
i
3/23/2021StephensBoost Price TargetBuy ➝ Overweight$50.00 ➝ $55.00High
i
3/23/2021KeyCorpBoost Price TargetOverweight$40.00 ➝ $50.00High
i
3/23/2021BenchmarkUpgradeHold ➝ Buy$54.00High
i
3/18/2021B. RileyReiterated RatingBuyLow
i
Rating by M. Wiesenberger at B. Riley
12/28/2020Northland SecuritiesBoost Price Target$35.00 ➝ $55.00N/A
i
Rating by Carl Byrnes at Northland Securities
11/9/2020KeyCorpInitiated CoverageOverweight$40.00Low
i
10/19/2020B. RileyBoost Price Target$30.00 ➝ $35.00Low
i
Rating by Marc Wiesenberger at B. Riley
9/23/2020B. RileyBoost Price Target$25.50 ➝ $30.00High
i
Rating by Marc Wiesenberger at B. Riley
9/22/2020Maxim GroupBoost Price Target$26.00 ➝ $32.00High
i
Rating by Jason McCarthy at Maxim Group
9/22/2020Lake Street CapitalBoost Price TargetBuy$29.00 ➝ $35.00High
i
9/22/2020Northland SecuritiesBoost Price TargetOutperform$27.00 ➝ $35.00Medium
i
Rating by Carl Byrnes at Northland Securities
9/22/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
i
9/18/2020CowenInitiated CoverageOutperform$33.00High
i
8/11/2020BenchmarkDowngradeBuy ➝ Hold$21.00High
i
8/7/2020Maxim GroupInitiated CoverageBuy$26.00High
i
Rating by Jason McCarthy at Maxim Group
8/7/2020Northland SecuritiesReiterated RatingBuy$28.00Low
i
Rating by Carl Byrnes at Northland Securities
7/10/2020B. RileyBoost Price TargetBuy$20.00 ➝ $25.50Low
i
Rating by M. Wiesenberger at B. Riley
7/8/2020Maxim GroupBoost Price TargetBuy$18.00 ➝ $26.00Low
i
Rating by Jason McCarthy at Maxim Group
7/8/2020Northland SecuritiesReiterated RatingBuy$24.00 ➝ $28.00Low
i
6/4/2020HC WainwrightReiterated RatingBuy$17.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/16/2020Maxim GroupReiterated RatingBuy$18.00High
i
Rating by Jason McCarthy at Maxim Group
5/15/2020StephensBoost Price TargetOverweight$23.00 ➝ $24.00High
i
Rating by Jacob Johnson at Stephens
5/6/2020OppenheimerReiterated RatingBuyHigh
i
5/5/2020HC WainwrightReiterated RatingBuy$17.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/4/2020B. RileyLower Price TargetBuy$24.00 ➝ $22.00High
i
Rating by M. Wiesenberger at B. Riley
3/23/2020HC WainwrightLower Price TargetBuy$26.00 ➝ $17.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/12/2020B. RileyLower Price TargetBuy$27.00 ➝ $24.00High
i
Rating by M. Wiesenberger at B. Riley
2/24/2020Lake Street CapitalInitiated CoverageBuy$25.00High
i
2/19/2020BenchmarkInitiated CoverageBuy$24.00High
i
2/6/2020B. RileyInitiated CoverageBuy$27.00High
i
Rating by M. Wiesenberger at B. Riley
1/7/2020StephensInitiated CoverageOverweight$23.00High
i
12/16/2019HC WainwrightReiterated RatingBuy$23.00 ➝ $26.00Low
i
Rating by R. Selvaraju at HC Wainwright
11/20/2019OppenheimerInitiated CoverageOutperform$22.00High
i
9/17/2019Maxim GroupSet Price TargetBuy$26.00Low
i
Rating by Jason McCarthy at Maxim Group
9/4/2019Northland SecuritiesBoost Price TargetOutperform$18.00 ➝ $22.00High
i
8/9/2019Maxim GroupSet Price TargetBuy$24.00High
i
Rating by Jason McCarthy at Maxim Group
7/22/2019HC WainwrightInitiated CoverageBuy ➝ Buy$23.00High
i
Rating by R. Selvaraju at HC Wainwright
7/9/2019Northland SecuritiesReiterated RatingBuy$18.00High
i
5/22/2019Maxim GroupSet Price TargetBuy$24.00Low
i
Rating by Jason McCarthy at Maxim Group
5/13/2019Northland SecuritiesReiterated RatingBuy$18.00Low
i
12/20/2018Janney Montgomery ScottUpgradeBuy$5.00Low
i
Rating by Paul Knight at Janney Montgomery Scott
11/9/2018B. RileySet Price TargetBuy$22.00Low
i
Rating by George Zavoico at B. Riley
10/3/2018B. RileySet Price TargetBuy ➝ Buy$22.00High
i
Rating by George Zavoico at B. Riley
9/5/2018Maxim GroupReiterated RatingBuy$26.00High
i
Rating by Jason McCarthy at Maxim Group
8/14/2018B. RileySet Price TargetBuy$23.00Low
i
Rating by George Zavoico at B. Riley
8/10/2018Northland SecuritiesReiterated RatingBuy$18.00Low
i
7/3/2018B. RileySet Price TargetBuy$19.00Low
i
Rating by George Zavoico at B. Riley
6/7/2018B. RileyInitiated CoverageBuy$14.00Low
i
Rating by George Zavoico at B. Riley
5/11/2018Maxim GroupBoost Price TargetBuy ➝ Buy$9.00 ➝ $12.00High
i
Rating by Jason McCarthy at Maxim Group
4/30/2018Maxim GroupSet Price TargetBuy$9.00Low
i
Rating by Jason McCarthy at Maxim Group
4/2/2018Maxim GroupReiterated RatingBuy$9.00High
i
Rating by Jason McCarthy at Maxim Group
3/19/2018Maxim GroupSet Price TargetBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
3/12/2018Northland SecuritiesInitiated CoverageOutperformHigh
i
3/9/2018Maxim GroupSet Price TargetBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
1/4/2018Maxim GroupSet Price TargetBuy$8.00High
i
Rating by Jason Kolbert at Maxim Group
11/30/2017Maxim GroupUpgradeBuy$8.00Low
i
Rating by Jason McCarthy at Maxim Group
11/10/2017Maxim GroupBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.00N/A
i
Rating by Jason McCarthy at Maxim Group
10/26/2017Maxim GroupReiterated RatingBuy$7.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/19/2017Maxim GroupSet Price TargetBuy$7.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/19/2017Maxim GroupBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00Low
i
Rating by Gabrielle Zhou at Maxim Group
8/11/2017Maxim GroupSet Price TargetBuy$6.00High
i
Rating by Gabrielle Zhou at Maxim Group
7/31/2017Maxim GroupReiterated RatingBuy$5.00Low
i
Rating by Jason Kolbert at Maxim Group
7/5/2017Maxim GroupReiterated RatingBuy$4.00High
i
Rating by Gabrielle Zhou at Maxim Group
7/5/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$2.62 ➝ $5.00High
i
6/14/2017Maxim GroupReiterated RatingBuy$4.00Low
i
Rating by Gabrielle Zhou at Maxim Group
5/13/2017Maxim GroupSet Price TargetBuy$4.00Medium
i
Rating by Gabrielle Zhou at Maxim Group
3/10/2017Maxim GroupReiterated RatingBuy ➝ Buy$3.00 ➝ $4.00High
i
Rating by Gabrielle Zhou at Maxim Group
1/19/2017Maxim GroupInitiated CoverageBuy$3.00N/A
i
9/13/2016Janney Montgomery ScottInitiated CoverageNeutral$2.10N/A
i
(Data available from 4/14/2016 forward)
BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; and liquid nitrogen laboratory freezers, cryogenic equipment, and accessories. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $34.90
$34.56
$34.90

50 Day Range

MA: $37.28
$32.95
$41.98

52 Week Range

Now: $34.90
$9.53
$47.97

Volume

3,811 shs

Average Volume

311,979 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of BioLife Solutions?

The following equities research analysts have issued research reports on BioLife Solutions in the last year: B. Riley, Benchmark Co., Cowen Inc, HC Wainwright, KeyCorp, Lake Street Capital, Maxim Group, Northland Securities, Oppenheimer Holdings Inc., Stephens, and Zacks Investment Research.
View the latest analyst ratings for BLFS.

What is the current price target for BioLife Solutions?

9 Wall Street analysts have set twelve-month price targets for BioLife Solutions in the last year. Their average twelve-month price target is $46.67, suggesting a possible upside of 34.7%. B. Riley has the highest price target set, predicting BLFS will reach $61.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for BioLife Solutions in the next year.
View the latest price targets for BLFS.

What is the current consensus analyst rating for BioLife Solutions?

BioLife Solutions currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLFS will outperform the market and that investors should add to their positions of BioLife Solutions.
View the latest ratings for BLFS.

What other companies compete with BioLife Solutions?

Other companies that are similar to BioLife Solutions include LivaNova, CONMED, InMode, Outset Medical, Natus Medical, AxoGen, TransMedics Group, Semler Scientific, ViewRay, Stereotaxis, Cutera, Zynex, Edap Tms, Second Sight Medical Products and BioSig Technologies.

How do I contact BioLife Solutions' investor relations team?

BioLife Solutions' physical mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider's listed phone number is 425-402-1400 and its investor relations email address is [email protected] The official website for BioLife Solutions is www.biolifesolutions.com.